After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Intellia Therapeutics Inc. (NTLA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.07, or 0.19%, to $37.58. The Intellia Therapeutics Inc. has recorded 13,376 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema.
NTLA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $37.51 and fluctuated between $38.49 as its day high and $37.10 as its day low. The current market capitalization of Intellia Therapeutics Inc. is $3.17B. A total of 1.0 million shares were traded on the day, compared to an average of 1.11M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NTLA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 13 BUYs and 0 SELLs from insiders. Insiders purchased 124,400 shares during that period but sold 0.
In the most recent transaction, Sepp-Lorenzino Laura sold 2,330 shares of NTLA for 38.48 per share on Jan 05. After the transaction, the EVP, Chief Scientific Officer now owns 17,629 company shares. In a previous transaction on Jan 04, Sepp-Lorenzino Laura sold 2,508 shares at 37.21 per share. NTLA shares that EVP, Chief Scientific Officer owns now total 19,959.
Among the insiders who sold shares, LEONARD JOHN M disposed of 6,673 shares on Jan 04 at a per-share price of $37.21. This resulted in the President and CEO holding 766,825 shares of NTLA after the transaction. In another insider transaction, Hicks Derek sold 1,812 shares at $37.21 per share on Jan 04. Company shares held by the EVP, Chief Business Officer now total 17,306.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NTLA in the last 3 months, the mean price target is $106.60 with high estimates of $167.00 and low estimates of $48.00. In terms of 52-week highs and lows, NTLA has a high of $108.00 and a low of $32.72.
As of this writing, NTLA has an earnings estimate of -$1.28 per share for the current quarter. EPS was calculated based on a consensus of 25 estimates, with a high estimate of -$0.28 per share and a lower estimate of -$1.56. The company reported an EPS of -$1.96 in the last quarter, which was -78.20% lower than expectations of -$1.1.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 28 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTLA is Sell with a score of 4.55. A total of 21 analysts rated the stock as Buy while 3 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.